Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06946199
PHASE1

An Open-label Study of Cizutamig in Refractory Seropositive Rheumatoid Arthritis

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate the safety and efficacy of BCMAxCD3 T-cell engager (cizutamig) in patients with refractory seropositive RA.

Official title: An Open-label Study Evaluating the Safety and Preliminary Clinical Activity of Cizutamig in Patients With Refractory Seropositive Rheumatoid Arthritis

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

28

Start Date

2025-06-23

Completion Date

2027-06

Last Updated

2026-01-12

Healthy Volunteers

No

Interventions

DRUG

Cizutamig

Cizutamig will be administered per the dose escalation cohort

BIOLOGICAL

Cizutamig

Cizutamig will be administered per the dose escalation cohort

Locations (1)

Wuhan Union Hospital

Wuhan, Hubei, China